Greater than the sum of our parts (Malaria case study)
Building climate-resilient, sustainable, and low-carbon health supply chains: key priorities for collective action
SafeBirth Africa: Reducing preventable deaths in childbirth
Maternal and newborn health
Unitaid and the Government of Spain
Unitaid’s climate and health strategy 2023-2027
Unitaid’s investment case 2023-2027, executive summary
Unitaid’s investment case 2023-2027
Unitaid Strategy 2023-2027
Maternal and newborn health
Women’s and children’s health
Building for sustainability: Accelerating regional manufacturing for diagnostics (FIND and Unitaid)
Meeting report: Strengthening cooperation to enable sustainable development and manufacturing of effective, quality and affordable diagnostic countermeasures (FIND and Unitaid)
Q&A: Monoclonal antibodies
From milligrams to megatons: A climate and nature assessment of 10 key health products
Executive summary: From milligrams to megatons: A climate and nature assessment of 10 key health products
Landscape of rapid diagnostic tests for severe bacterial infections in advanced HIV Disease
The health products manufacturers support platform: Enhancing regional manufacturing of health technologies in Africa
Novel business models for accessible monoclonal antibodies for infectious diseases in LMICS: Multistakeholder meeting recommendations
Unitaid audited financial report for the year ended 31 December 2021
Unitaid audited financial report for the year ended 31 December 2020
Unitaid audited financial report for the year ended 31 December 2019
Unitaid audited financial report for the year ended 31 December 2018
ACT Forecasting Report Q1-2012
Key Performance Indicators 2012
HIV, Tuberculosis and Malaria medicines landscape
Unitaid audited financial report for the period 2010-2011
Malaria diagnostics technology landscape
HIV/AIDS diagnostics technology landscape – semi-annual update
HIV simple/rapid, EIA, and supplemental test market analysis
